About Veracyte

Veracyte is headquartered in South San Francisco, California, with offices in San Diego as well as Austin, Texas, and Haifa, Israel.

Veracyte offers laboratory developed tests (LDTs) performed in our CLIA-certified, high-complexity labs for four cancer types: thyroid, prostate, bladder, and breast.

The Prosigna Breast Cancer Prognostic Gene Signature Assay is available as a CE-IVD test outside the US — to find out if it is available in your country, or for information about reimbursement and insurance coverage, contact us at [email protected].

Our tests provide clinicians with insights based on each patient’s unique tumor biology to help guide personalized treatment decisions. To learn more, visit Technology and Pipeline.

Investors can trade Veracyte publicly on the Nasdaq Global Market under the ticker symbol VCYT. The company went public in October 2013.

In the United States, healthcare providers order Veracyte tests. Patients cannot order tests directly. A healthcare provider must order them as part of clinical cancer care.

For our in vitro diagnostic (IVD) tests, global healthcare providers or local hospital labs order these tests. Patients cannot order IVDs directly.

We work to make our laboratory developed tests (LDTs) accessible to patients. Medicare and many commercial insurance plans cover our molecular tests in the United States. We also offer billing support, financial assistance, and flexible payment options. Some restrictions apply.

We share whole-genome data with researchers through our GRID database and research partnerships. This helps advance discoveries in prostate, bladder, and thyroid cancers. We partner with clinicians, academic institutions, and research groups worldwide.